Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic

Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
Photo: MIKE SEGAR/REUTERS / X90033
Photo: MIKE SEGAR/REUTERS / X90033
by mikkel aabenhus hemmingsen, translated by catherine brett

According to the CEO of an influential diabetes center in Copenhagen, Novo Nordisk has gained a worthy opponent within the diabetes indication in the form of Eli Lilly’s Mounjaro (tirzepatide), which was recently approved in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading